Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:38 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

ClinicalTrials.gov · NCT06829355 · Registry updated: 2025-02-17

Condition / research focus: MCRC
Sponsor: Beijing Friendship Hospital
Countries with listed sites: China
Registry dates and results: Start: 2025-02-11. Completion: 2027-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (Thymosin alpha 1, Ta1) (drug)
Regorafenib (BAY 73-4506) (drug)
Tislelizumab (BGB-A317) (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Beijing Friendship Hospital, Capital Medical University
Beijing, China, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

ClinicalTrials.gov · NCT06607926 · Registry updated: 2024-09-23

Condition / research focus: Resectable Non-Small-Cell Lung Cancer
Sponsor: Xuanwu Hospital, Beijing
Countries with listed sites: China
Registry dates and results: Start: 2024-10-15. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: thymalfasin
Tislelizumab (drug)
Platinum-doublet chemotherapy (drug)

Where the study takes place — 1 listed sites

Xuanwu Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

ClinicalTrials.gov · NCT06584006 · Registry updated: 2024-09-19

Condition / research focus: Hematological Malignancy; Lymphocytopenia
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2024-09-01. Completion: 2028-02-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections (drug) — also listed as: Combination Therapy Group
Recombinant Human Interleukin-2 Injections (drug) — also listed as: Monotherapy Group

Where the study takes place — 1 listed sites

Zhijuan Lin
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Immuno-effect of Tα1 for Stage I NSCLC

ClinicalTrials.gov · NCT06598839 · Registry updated: 2024-09-19

Condition / research focus: Non Small Cell Lung Cancer
Sponsor: Yousheng Mao
Countries with listed sites: China
Registry dates and results: Start: 2024-06-30. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: Tα1, Thymalfasin

Where the study takes place — 1 listed sites

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

ClinicalTrials.gov · NCT06573398 · Registry updated: 2024-08-27

Condition / research focus: Carcinoma, Pancreatic Ductal
Sponsor: Ruijin Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-09-01. Completion: 2027-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin (combination_product)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Thymosin Alpha-1 for irAE Secondary to ICIs

ClinicalTrials.gov · NCT06178146 · Registry updated: 2023-12-20

Condition / research focus: IrAE
Sponsor: Jun Wang
Countries with listed sites: China
Registry dates and results: Start: 2023-09-01. Completion: 2025-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: thymalfasin
Immunosuppressant (drug) — also listed as: Prednisone, Cortisone, Mycophenolate Mofetil, Tacrolimus

Where the study takes place — 1 listed sites

The first affiliated hospital of Shandong First Medical University
Jinan, Shandong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Abscopal Effect for Metastatic Colorectal Cancer

ClinicalTrials.gov · NCT02535988 · Registry updated: 2023-09-21

Condition / research focus: Colorectal Cancer; Metastatic Colorectal Cancer; Thymalfasin
Sponsor: Zhejiang Provincial People's Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-09. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Radiation therapy (radiation)
Thymalfasin (drug) — also listed as: ZADAXIN's®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

ClinicalTrials.gov · NCT04963712 · Registry updated: 2023-07-18

Condition / research focus: HIV-1-infection
Sponsor: Shanghai Public Health Clinical Center
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zadaxin (drug) — also listed as: Thymosin α1

Where the study takes place — 1 listed sites

Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

The Efficacy and Safety of Ta1 for Sepsis

ClinicalTrials.gov · NCT02867267 · Registry updated: 2023-04-10

Condition / research focus: Sepsis
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2016-09-06. Completion: 2021-03-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin alpha 1 (drug) — also listed as: thymalfasin
Placebo (other)

Where the study takes place — 22 listed sites

Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First People's Hospital of Foshan
Foshan, Guangdong, China
Site recruitment: Not reported
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Site recruitment: Not reported
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Zhuhai People's Hospital
Zhuhai, Guangdong, China
Site recruitment: Not reported
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Nanjing General Hospital of Nanjing Military Commend
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported
Shandong Provincial Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Zhejiang Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

ClinicalTrials.gov · NCT05790447 · Registry updated: 2023-03-30

Condition / research focus: Advanced Solid Tumor; Refractory Tumor
Sponsor: Second Affiliated Hospital of Soochow University
Countries with listed sites: China
Registry dates and results: Start: 2023-04-01. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (drug) — also listed as: Thymosin alpha-1
Radiotherapy (radiation)
PD-1/PD-L1 inhibitor (drug) — also listed as: PD-1/PD-L1 antibody
GM-CSF (drug) — also listed as: :Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor for Injection

Where the study takes place — 1 listed sites

The Second Affiliated Hospital of SchoowUniversity
Suzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

ClinicalTrials.gov · NCT04487444 · Registry updated: 2023-02-14

Condition / research focus: Covid19
Sponsor: Rhode Island Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-10. Completion: 2023-02-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (drug) — also listed as: Thymosin alpha 1, ZADAXIN (brand name), Ta1 (abbreviation)

Where the study takes place — 1 listed sites

The Miriam Hospital
Providence, Rhode Island, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

ClinicalTrials.gov · NCT05658692 · Registry updated: 2022-12-21

Condition / research focus: Acute Respiratory Distress Syndrome
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2022-10-01. Completion: 2023-12 (may be estimated). No results posted in this registry response.

Products and interventions (14)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

protective ventilation (device)
prone position ventilation (behavioral)
glucocorticoid therapy (drug) — also listed as: Dexamethasone, Hydrocortisone
restrictive fluid resuscitation (other)
Thymosin Alpha (biological)
Muscle relaxant therapy (drug) — also listed as: Vecuronium Bromide, Succinylcholine
Integrated Chinese and Western Medicine Treatment (other)
statin therapy (drug) — also listed as: Simvastatin, Rosuvastatin
anti-infective treatment (combination_product)
Extracorporeal Membrane Oxygenation（ECMO） (device)
stem cell therapy (genetic)
Sedative analgesia/muscle relaxant therapy (drug) — also listed as: Propofol, midazolam, dexmedetomidine
inotropes therapy (drug) — also listed as: Dopamine, Olprinone, Levosimendan
Vasoactive drug therapy (drug) — also listed as: Norepinephrine, epinephrine, metaraminol, isoproterenol

Where the study takes place — 11 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Recruiting
West China Hospital，Sichuan University
Chengdu, China
Site recruitment: Recruiting
Guangdong Provincial People's Hospital
Guangdong, China
Site recruitment: Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Site recruitment: Recruiting
Lanxi People's Hospital
Lanxi, China
Site recruitment: Recruiting
Ningbo First Hospital
Ningbo, China
Site recruitment: Recruiting
Zhognshang hospital, Fudan University
Shanghai, China
Site recruitment: Recruiting
Taizhou Hosptial of Zhejiang Province
Taizhou, China
Site recruitment: Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Site recruitment: Recruiting
Wuhan University Renmin Hospital
Wuhan, China
Site recruitment: Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

ClinicalTrials.gov · NCT05487469 · Registry updated: 2022-08-04

Condition / research focus: Rheumatic Heart Disease; Cardiopulmonary Bypass; Immunotherapy
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Blank Control (other)

Where the study takes place — 1 listed sites

The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

ClinicalTrials.gov · NCT03659578 · Registry updated: 2022-01-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-09. Completion: 2021-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Concurrent chemotherapy (drug)
split-course radiotherapy (radiation)
thymosin alpha 1 (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

ClinicalTrials.gov · NCT05086614 · Registry updated: 2021-10-21

Condition / research focus: Stage II Colorectal Cancer; Stage III Colorectal Cancer
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2021-04-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: Thymalfasin

Where the study takes place — 1 listed sites

Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

ClinicalTrials.gov · NCT03082885 · Registry updated: 2021-08-16

Condition / research focus: Liver Failure
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2017-04-10. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug) — also listed as: Zadaxin

Where the study takes place — 1 listed sites

Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Long-term Prognosis of Patients With Sepsis After Immunotherapy

ClinicalTrials.gov · NCT04901104 · Registry updated: 2021-05-25

Condition / research focus: Long-term Effects of Thymosin Alpha 1 Treatment
Sponsor: Sun Yat-sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-07-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

ClinicalTrials.gov · NCT02473406 · Registry updated: 2021-04-05

Condition / research focus: Pancreatitis, Acute Necrotizing
Sponsor: Weiqin Li
Countries with listed sites: China
Registry dates and results: Start: 2018-03-27. Completion: 2021-03-24 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: Thymosin Group
normal saline (drug) — also listed as: Placebo Group

Where the study takes place — 2 listed sites

Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jinling Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

ClinicalTrials.gov · NCT04524169 · Registry updated: 2020-08-26

Condition / research focus: Osteoporotic Pain
Sponsor: RenJi Hospital
Countries with listed sites: China
Registry dates and results: Start: 2020-11-01. Completion: 2021-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 1 listed sites

Diansan Su
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

ClinicalTrials.gov · NCT04320238 · Registry updated: 2020-03-31

Condition / research focus: 2019 Novel Coronavirus Infection
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2020-01-21. Completion: 2020-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant human interferon Alpha-1b (drug) — also listed as: interferon α
thymosin alpha 1 (drug) — also listed as: thymosin α

Where the study takes place — 1 listed sites

Taihe Hospital
Shiyan, Hubei, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:38 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

ClinicalTrials.gov · NCT06829355 · Registry updated: 2025-02-17

Condition / research focus: MCRC
Sponsor: Beijing Friendship Hospital
Countries with listed sites: China
Registry dates and results: Start: 2025-02-11. Completion: 2027-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (Thymosin alpha 1, Ta1) (drug)
Regorafenib (BAY 73-4506) (drug)
Tislelizumab (BGB-A317) (drug)

Where the study takes place — 1 listed sites

Beijing Friendship Hospital, Capital Medical University
Beijing, China, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

ClinicalTrials.gov · NCT06607926 · Registry updated: 2024-09-23

Condition / research focus: Resectable Non-Small-Cell Lung Cancer
Sponsor: Xuanwu Hospital, Beijing
Countries with listed sites: China
Registry dates and results: Start: 2024-10-15. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: thymalfasin
Tislelizumab (drug)
Platinum-doublet chemotherapy (drug)

Where the study takes place — 1 listed sites

Xuanwu Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

ClinicalTrials.gov · NCT06584006 · Registry updated: 2024-09-19

Condition / research focus: Hematological Malignancy; Lymphocytopenia
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2024-09-01. Completion: 2028-02-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections (drug) — also listed as: Combination Therapy Group
Recombinant Human Interleukin-2 Injections (drug) — also listed as: Monotherapy Group

Where the study takes place — 1 listed sites

Zhijuan Lin
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Immuno-effect of Tα1 for Stage I NSCLC

ClinicalTrials.gov · NCT06598839 · Registry updated: 2024-09-19

Condition / research focus: Non Small Cell Lung Cancer
Sponsor: Yousheng Mao
Countries with listed sites: China
Registry dates and results: Start: 2024-06-30. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: Tα1, Thymalfasin

Where the study takes place — 1 listed sites

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

ClinicalTrials.gov · NCT06573398 · Registry updated: 2024-08-27

Condition / research focus: Carcinoma, Pancreatic Ductal
Sponsor: Ruijin Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-09-01. Completion: 2027-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin (combination_product)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Thymosin Alpha-1 for irAE Secondary to ICIs

ClinicalTrials.gov · NCT06178146 · Registry updated: 2023-12-20

Condition / research focus: IrAE
Sponsor: Jun Wang
Countries with listed sites: China
Registry dates and results: Start: 2023-09-01. Completion: 2025-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: thymalfasin
Immunosuppressant (drug) — also listed as: Prednisone, Cortisone, Mycophenolate Mofetil, Tacrolimus

Where the study takes place — 1 listed sites

The first affiliated hospital of Shandong First Medical University
Jinan, Shandong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Abscopal Effect for Metastatic Colorectal Cancer

ClinicalTrials.gov · NCT02535988 · Registry updated: 2023-09-21

Condition / research focus: Colorectal Cancer; Metastatic Colorectal Cancer; Thymalfasin
Sponsor: Zhejiang Provincial People's Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-09. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Radiation therapy (radiation)
Thymalfasin (drug) — also listed as: ZADAXIN's®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

ClinicalTrials.gov · NCT04963712 · Registry updated: 2023-07-18

Condition / research focus: HIV-1-infection
Sponsor: Shanghai Public Health Clinical Center
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zadaxin (drug) — also listed as: Thymosin α1

Where the study takes place — 1 listed sites

Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

The Efficacy and Safety of Ta1 for Sepsis

ClinicalTrials.gov · NCT02867267 · Registry updated: 2023-04-10

Condition / research focus: Sepsis
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2016-09-06. Completion: 2021-03-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin alpha 1 (drug) — also listed as: thymalfasin
Placebo (other)

Where the study takes place — 22 listed sites

Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First People's Hospital of Foshan
Foshan, Guangdong, China
Site recruitment: Not reported
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Site recruitment: Not reported
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Zhuhai People's Hospital
Zhuhai, Guangdong, China
Site recruitment: Not reported
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Nanjing General Hospital of Nanjing Military Commend
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported
Shandong Provincial Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Zhejiang Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

ClinicalTrials.gov · NCT05790447 · Registry updated: 2023-03-30

Condition / research focus: Advanced Solid Tumor; Refractory Tumor
Sponsor: Second Affiliated Hospital of Soochow University
Countries with listed sites: China
Registry dates and results: Start: 2023-04-01. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (drug) — also listed as: Thymosin alpha-1
Radiotherapy (radiation)
PD-1/PD-L1 inhibitor (drug) — also listed as: PD-1/PD-L1 antibody
GM-CSF (drug) — also listed as: :Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor for Injection

Where the study takes place — 1 listed sites

The Second Affiliated Hospital of SchoowUniversity
Suzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

ClinicalTrials.gov · NCT04487444 · Registry updated: 2023-02-14

Condition / research focus: Covid19
Sponsor: Rhode Island Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-10. Completion: 2023-02-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (drug) — also listed as: Thymosin alpha 1, ZADAXIN (brand name), Ta1 (abbreviation)

Where the study takes place — 1 listed sites

The Miriam Hospital
Providence, Rhode Island, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

ClinicalTrials.gov · NCT05658692 · Registry updated: 2022-12-21

Condition / research focus: Acute Respiratory Distress Syndrome
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2022-10-01. Completion: 2023-12 (may be estimated). No results posted in this registry response.

Products and interventions (14)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

protective ventilation (device)
prone position ventilation (behavioral)
glucocorticoid therapy (drug) — also listed as: Dexamethasone, Hydrocortisone
restrictive fluid resuscitation (other)
Thymosin Alpha (biological)
Muscle relaxant therapy (drug) — also listed as: Vecuronium Bromide, Succinylcholine
Integrated Chinese and Western Medicine Treatment (other)
statin therapy (drug) — also listed as: Simvastatin, Rosuvastatin
anti-infective treatment (combination_product)
Extracorporeal Membrane Oxygenation（ECMO） (device)
stem cell therapy (genetic)
Sedative analgesia/muscle relaxant therapy (drug) — also listed as: Propofol, midazolam, dexmedetomidine
inotropes therapy (drug) — also listed as: Dopamine, Olprinone, Levosimendan
Vasoactive drug therapy (drug) — also listed as: Norepinephrine, epinephrine, metaraminol, isoproterenol

Where the study takes place — 11 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Recruiting
West China Hospital，Sichuan University
Chengdu, China
Site recruitment: Recruiting
Guangdong Provincial People's Hospital
Guangdong, China
Site recruitment: Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Site recruitment: Recruiting
Lanxi People's Hospital
Lanxi, China
Site recruitment: Recruiting
Ningbo First Hospital
Ningbo, China
Site recruitment: Recruiting
Zhognshang hospital, Fudan University
Shanghai, China
Site recruitment: Recruiting
Taizhou Hosptial of Zhejiang Province
Taizhou, China
Site recruitment: Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Site recruitment: Recruiting
Wuhan University Renmin Hospital
Wuhan, China
Site recruitment: Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

ClinicalTrials.gov · NCT05487469 · Registry updated: 2022-08-04

Condition / research focus: Rheumatic Heart Disease; Cardiopulmonary Bypass; Immunotherapy
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Blank Control (other)

Where the study takes place — 1 listed sites

The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

ClinicalTrials.gov · NCT03659578 · Registry updated: 2022-01-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-09. Completion: 2021-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Concurrent chemotherapy (drug)
split-course radiotherapy (radiation)
thymosin alpha 1 (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

ClinicalTrials.gov · NCT05086614 · Registry updated: 2021-10-21

Condition / research focus: Stage II Colorectal Cancer; Stage III Colorectal Cancer
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2021-04-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug) — also listed as: Thymalfasin

Where the study takes place — 1 listed sites

Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

ClinicalTrials.gov · NCT03082885 · Registry updated: 2021-08-16

Condition / research focus: Liver Failure
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2017-04-10. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug) — also listed as: Zadaxin

Where the study takes place — 1 listed sites

Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Long-term Prognosis of Patients With Sepsis After Immunotherapy

ClinicalTrials.gov · NCT04901104 · Registry updated: 2021-05-25

Condition / research focus: Long-term Effects of Thymosin Alpha 1 Treatment
Sponsor: Sun Yat-sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-07-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

ClinicalTrials.gov · NCT02473406 · Registry updated: 2021-04-05

Condition / research focus: Pancreatitis, Acute Necrotizing
Sponsor: Weiqin Li
Countries with listed sites: China
Registry dates and results: Start: 2018-03-27. Completion: 2021-03-24 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: Thymosin Group
normal saline (drug) — also listed as: Placebo Group

Where the study takes place — 2 listed sites

Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jinling Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

ClinicalTrials.gov · NCT04524169 · Registry updated: 2020-08-26

Condition / research focus: Osteoporotic Pain
Sponsor: RenJi Hospital
Countries with listed sites: China
Registry dates and results: Start: 2020-11-01. Completion: 2021-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 1 listed sites

Diansan Su
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

ClinicalTrials.gov · NCT04320238 · Registry updated: 2020-03-31

Condition / research focus: 2019 Novel Coronavirus Infection
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2020-01-21. Completion: 2020-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant human interferon Alpha-1b (drug) — also listed as: interferon α
thymosin alpha 1 (drug) — also listed as: thymosin α

Where the study takes place — 1 listed sites

Taihe Hospital
Shiyan, Hubei, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →